BEIJING and CLAREMONT, Calif., May 13 /Xinhua-PRNewswire-FirstCall/ -- Kiwa Bio-Tech Products Group Corporation (OTC Bulletin Board: KWBT) announced finalization of an agreement establishing a joint venture company capable of producing Kiwa's AF-01 anti-viral product.
On May 9, General Manager of Shijiazhuang Huaxing Animal Medicine Co., Ltd. (''Huaxing''), Mr. Ruijun Li and his associates visited Kiwa's headquarters in Beijing for the final round of negotiations toward setting up a proposed joint-venture. Both parties had extensively negotiated on the terms of the joint-venture contract and finally confirmed all terms of the contract.
The signing ceremony will be held next week, after the company name is approved by the local Administration of Industry and Commerce.
ABOUT AF-01 ANTI-VIRAL FEED ENHANCEMENT AND AEROSOL
In May 2006, Kiwa acquired AF-01 Anti-viral Aerosol technology for veterinary medicine applications including the exclusive production right and other related rights to produce an anti-viral aerosol drug for use with animals from Jinan Kelongboao Bio-Tech Co., Ltd. ("JKB"), which is affiliated with Chinese Academy of Medical Sciences. The AF-01 aerosol technology is a broad-spectrum anti-viral agent with potent inhibitory and/or viricidal effects on a variety of RNA viruses found in animals and fowls such as bird flu. Kiwa's hope is to develop a commercialized product in the form of a spray for applying in fowl houses and other animal holding facilities to prevent and cure virus-caused diseases.
ABOUT SHIJIAZHUANG HUAXING ANIMAL MEDICINE CO., LTD.
Huaxing was founded in 1996. Huaxing is supported by animal husbandry
and veterinary medicine agencies at both provincial and municipal levels.
Huaxing has focused on building strong co-operative relationships with
academic institutions such as the Agricultural University of Heibei and
Hebei University of Science & Technology. Huaxing has developed: 12-series
|SOURCE Kiwa Bio-Tech Products Group Corporation|
Copyright©2008 PR Newswire.
All rights reserved